Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02873390
Recruitment Status : Unknown
Verified August 2016 by Ningbo Cancer Hospital.
Recruitment status was:  Recruiting
First Posted : August 19, 2016
Last Update Posted : October 7, 2016
Information provided by (Responsible Party):
Ningbo Cancer Hospital

Brief Summary:

To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer.

Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.

Condition or disease Intervention/treatment Phase
PD-1 Antibody CAR-T Cells Advanced Malignancies Biological: HerinCAR-PD1 cells Phase 1 Phase 2

Detailed Description:
A total of 20 patients may be enrolled over a period of 1-2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
Study Start Date : August 2016
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Family Issues

Arm Intervention/treatment
Experimental: HerinCAR-PD1 cells
Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
Biological: HerinCAR-PD1 cells
herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.

Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 2 years ]
  2. Disease control rate,(DCR) [ Time Frame: 2 years ]
  3. Overall survival [ Time Frame: 2 years ]
  4. Progress-free survival(PFS) [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Quality of life [ Time Frame: 2 years ]
    Questionnaire will be used.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18~80 years old, male or female;
  2. Life expectancy≥6 months;
  3. ECOG score: 0-2;
  4. Advanced Solid Tumor were diagnosed by histology and cytology;
  5. Enough venous channel,no other contraindications to the separation and collection of white blood cells;
  6. Immunohistochemistry and RT-PCR technology will be used to determine the positive EGFR family (including EGFR, HER2, HER4) and EGFRVIII、IGF1R protein. At least one protein expressed in immunohistochemical tumor tissue should be no less than grade 2 or 2+ scores. The levels of protein are defined as follows: (according to cell staining) : grade 0: without staining; grade 1: 1-25%; grade 2: 26-50% and grade 3: 51-100%; (According to the intensity): negative; 1+; 2+ and 3+;
  7. Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x10*9/L, hemoglobin≥85g/L; lymphocyte ≥0.7×109/L, total bilirubin less than 2.5 times of the normal level; ALT and AST less than 2.5 times of the normal level; serum creatinine less than 1.5 times of the normal level;
  8. Signed informed consent;
  9. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 4 months following the cells transfusion.
  10. Disease progression and the current treatment is invalid.
  11. The treatment effect is not ideal after receiving 2 line therapy at least and willing to join in clinical trials

Exclusion Criteria:

  1. Expected Overall survival < 6 months;
  2. Patients with uncontrolled hypertension,unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> Class II, NYHA), or myocardial infarction within 6 months.
  3. Abnormal lung function: FEV (forced expiratory volume) < 30% prediction, DLCO (diffusing capacity of the lung for carbon monoxide) < 30% prediction, blood oxygen saturation < 90%;
  4. Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;
  5. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.
  6. Uncontrolled active infection.
  7. Serious chronic disease of critical organs such as kidney and liver. Kidney function more than CKD stage I,and liver function less than the Child - Pugh class B;
  8. Long-term use or being used of immunosuppressive drugs with autoimmune diseases
  9. Glucocorticoid is needed in a long term.
  10. Currently (within 30 days) enrolled in another clinical trial.
  11. Pregnancy or breastfeeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02873390

Layout table for location contacts
Contact: Bi Wang 86-13310088259

Layout table for location information
China, Zhejiang
Ningbo No.5 Hospital (Ningbo Cancer Hospital) Recruiting
Ningbo, Zhejiang, China
Contact: Bi Wan    86-13310088259   
Contact: Jiangtao Wang    86-15888102792      
Sponsors and Collaborators
Ningbo Cancer Hospital
Layout table for investigator information
Study Director: Jiangtao Wang Ningbo No.5 Hospital (Ningbo Cancer Hospital)
Study Chair: Huajun Jin Shanghai Cell Therapy Research Institute
Study Chair: Qijun Qian Shanghai Cell Therapy Research Institute
Layout table for additonal information
Responsible Party: Ningbo Cancer Hospital Identifier: NCT02873390    
Other Study ID Numbers: NBWYKY2016-06-001/002/003
First Posted: August 19, 2016    Key Record Dates
Last Update Posted: October 7, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Ningbo Cancer Hospital:
PD-1 Antibody
CAR-T Cells
EGFR family
Advanced Malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms